Autor según el artículo: Laporte-Amargos J., Gudiol C., Arnan M., Puerta-Alcalde P., Carmona-Torre F., Huguet M., Albasanz-Puig A., Parody R., Garcia-Vidal C., Del Pozo J.L., Batlle M., Tebé C., Rigo-Bonnin R., Muñoz C., Padullés A., Tubau F., Videla S., Sureda A., Carratalà J.

Departamento: Ciències Mèdiques Bàsiques

Autor/es de la URV: TEBÉ CORDOMÍ, CRISTIAN

Resumen: © 2020 The Author(s). Background: Febrile neutropaenia (FN) is a very common complication in patients with haematological malignancies and is associated with considerable morbidity and mortality. Broad-spectrum antipseudomonal β-lactam antibiotics (BLA) are routinely used for the treatment of cancer patients with FN. However, the clinical efficacy of BLA may be diminished in these patients because they present with pathophysiological variations that compromise the pharmacokinetic (PK) parameters of these antibiotics. Optimised administration of BLA in prolonged infusions has demonstrated better clinical outcomes in critically ill patients. However, there is a paucity of data on the usefulness of this strategy in patients with FN. The aim of this study is to test the hypothesis that the administration of BLA would be clinically more effective by extended infusion (EI) than by intermittent infusion (II) in haematological patients with FN. Methods: A randomised, multicentre, open-label, superiority clinical trial will be performed. Patients with haematological malignancies undergoing chemotherapy or haematopoietic stem-cell transplant and who have FN and receive empirical antibiotic therapy with cefepime, piperacillin-tazobactam or meropenem will be randomised (1:1) to receive the antibiotic by EI (during half the time of the dosing interval) in the study group, or by II (30 min) in the control group. The primary endpoint will be clinical efficacy, defined as defervescence without modifying the antibiotic treatment administered within the first 5 days of therapy. The primary endpoint will be analysed in the intention-to-treat population. The secondary endpoints will be pharmacokinetic/pharmacodynamic (PK/PD) target achievement, bacteraemia clearance, decrease in C-reactive protein, overall (30-day) case-fatality rate, adverse events and development of a population PK model of the BLA studied. Discussion: Data on the usefulness of BLA administration in patients with FN are scant. Only three clinical studies addressing this issue have been published thus far, with contradictory results. Moreover, these studies had some methodological flaws that limit the interpretation of their findings. If this randomised, multicentre, phase IV, open-label, superiority clinical trial validates the hypothesis that the administration of BLA is clinically more effective by EI than by II in haematological patients with FN, then the daily routine management of these high-risk patients could be changed to improve their outcomes. Trial registration: European Clinical Trials Database: EudraCT 2018-001476-37. ClinicalTrials.gov, ID: NCT04233996.

Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/

Direcció de correo del autor: cristian.tebe@urv.cat

ISSN: 17456215

Identificador del autor: 0000-0003-2320-1385

Fecha de alta del registro: 2020-09-04

Versión del articulo depositado: info:eu-repo/semantics/publishedVersion

Enlace a la fuente original: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04323-0

URL Documento de licencia: http://repositori.urv.cat/ca/proteccio-de-dades/

DOI del artículo: 10.1186/s13063-020-04323-0

Entidad: Universitat Rovira i Virgili

Año de publicación de la revista: 2020

Tipo de publicación: Journal Publications